Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 8/20 | 0.34 |
| ▸ | HTR2C | P28335 | 8/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26881121 | 1.00 | PDE10A (0.34) | PDE10AHTR2AHTR2CUSP30DDR1 | |
| SCHEMBL16072934 | 1.00 | PDE10A (0.34) | PDE10AHTR2AHTR2CUSP30DDR1 | |
| SCHEMBL10205104 | 0.89 | HTR2A (0.39) | HTR2AHTR2C | |
| SCHEMBL21935713 | 0.86 | HTR2A (0.35) | PDE10AHTR2AHTR2CUSP30 | |
| SCHEMBL8260660 | 0.78 | — | — | |
| SCHEMBL19176922 | 0.77 | HTR2A (0.32) | HTR2AHTR2C | |
| SCHEMBL731310 | 0.77 | HRH4 (0.33) | — | |
| SCHEMBL8260570 | 0.77 | HRH4 (0.33) | — | |
| SCHEMBL679560 | 0.77 | HRH4 (0.33) | — | |
| SCHEMBL12439352 | 0.76 | HTR2A (0.44) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-10464947-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| US-7772239-B2 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070923-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-03-20 | — | — | US | disclosed |
| US-7317022-B2 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | HTR4, HTR5A, HTR1A | PDE10A 996/4885HTR2A 7/4885HTR2C 4/4885 |
| US-20080070923-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | PDE10A 979/4885HTR2A 8/4885HTR2C 4/4885 |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | PDE10A 941/4885HTR2A 3995/4885HTR2C 3480/4885 |
| US-10464947-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | PDE10A 4371/4885HTR2A 3190/4885HTR2C 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.